Allogeneic bone marrow transplantation in Korea: 1983-92.
Allogeneic bone marrow transplantation in Korea: 1983-92.
复制标题
韩国同种异体骨髓移植：1983-92。
DOI：
--
复制
发表时间：
1994
影响因子：
4.8
通讯作者：
H. K. Kim
中科院分区：
文献类型：
--
作者：
D. J. Kim;C. C. Kim;B. K. Kim;D. Kim;J. W. Lee;J. Jin;C. W. Han;W. Min;C. Park;H. K. Kim
1983年3月至1992年12月，我们为178例造血干细胞疾病患者进行了异基因骨髓移植，其中急性髓细胞性白血病（AML）48例，急性淋巴细胞性白血病（ALL）27例，慢性髓细胞性白血病（CML）40例，重型再生障碍性贫血（SAA）55例，骨髓增生异常综合征（MDS）6例，非霍奇金淋巴瘤和混合型白血病各1例。48例AML中有25例处于无病生存期（DFS）。27例ALL中有15例未维持缓解。40例CML中有24例处于DFS。55例SAA患者中有44例存活良好。比较标准AML（≤ CR 1：21/31（68%））和高危AML（≥ CR2：4/17（24%））的生存率，我们的数据表明高危AML的准备方案不足以根除晚期AML中的残留疾病。虽然我们的病例有限，随访时间短，但ALL的结果（总体：56%，标准风险（成人<或= CR 1，儿童<或= CR2：10/14（71%）和高风险））（成人>或= CR2，儿童> CR2）：13例中的5例（38%））和CML（总体：60%; CP：27例中的19例（70%），AP或BC：13例中的5例（38%））是有希望的。SAA的5年生存率为80 ± 4年。（250字处删节）
Between March 1983 and December 1992, we performed 178 allogeneic BMTs for patients with hematopoietic stem cell disorders: 48 acute myelogenous leukemia (AML), 27 acute lymphoblastic leukemia (ALL), 40 chronic myelogenous leukemia (CML), 55 severe aplastic anemia (SAA), 6 myelodysplastic syndrome (MDS), 1 non-Hodgkin's lymphoma and 1 hybrid leukemia. Twenty-five of 48 AML are in disease-free survival (DFS). Fifteen of 27 ALL are in unmaintained remission. Twenty-four of 40 CML are in DFS. Forty-four out of 55 SAA patients are alive and well. Comparing the survival between standard (< or = CR1: 21 of 31 (68%)) and high risk (> or = CR2: 4 of 17 (24%)) AML, our data suggest that the preparative regimen for high risk AML was not potent enough to eradicate the residual disease in advanced AML. Although our cases are limited and the follow-up period is short, the result of ALL (overall: 56%, standard risk (adult < or = CR1, children < or = CR2: 10 of 14 (71%) and high risk (adult > or = CR2, children > CR2): 5 of 13 (38%)) and CML (overall: 60%; CP: 19 of 27 (70%), AP or BC: 5 of 13 (38%)) are promising. The probability of 5 year survival of SAA was 80 +/- 4 years.(ABSTRACT TRUNCATED AT 250 WORDS)